Haleon US Holdings LLC Initiates Class I Recall of Robitussin Honey CF Max Nighttime Adult Due to Microbial Contamination
Haleon US Holdings LLC has initiated a Class I recall for 21,900 bottles of Robitussin Honey CF Max Nighttime Adult nationwide due to microbial contamination. This presents a high risk of serious adverse health consequences, demanding immediate action from procurement, regulatory, and supply chain leaders to mitigate disruption and ensure patient safety.
FDA Class I Recall: Microbial Contamination in Robitussin Honey CF Max Nighttime Adult
Haleon US Holdings LLC, based in Warren, NJ, has initiated a voluntary, firm-initiated Class I recall for specific lots of its Robitussin Honey CF Max Nighttime Adult product. This critical action, designated recall number D-0317-2024 by the FDA, stems from confirmed microbial contamination within the non-sterile liquid formulation. The affected product, an 8 FL OZ (237 mL) bottle containing Acetaminophen 650 mg and Diphenhydramine HCl 25mg, was distributed nationwide across the USA. A total of 21,900 bottles from lots T08740 and T08742, with an expiration date of June 30, 2026, are impacted. The FDA's Class I classification signifies that there is a reasonable probability that use of, or exposure to, the violative product will cause serious adverse health consequences or death. For procurement directors, this means an immediate need to halt all distribution and sales of the identified Robitussin product. Supply chain VPs must ensure robust reverse logistics are in place to retrieve affected stock efficiently from all points of distribution. Regulatory affairs heads must understand that a Class I recall demands swift and thorough investigation into the root cause of contamination and implementation of corrective and preventive actions (CAPAs) to prevent recurrence. Business development executives should note the potential market vacuum created by this significant withdrawal, particularly for combination cough and cold remedies, and assess opportunities for alternative products or formulations.
Recalling Entity Profile: Haleon US Holdings LLC and Affected Product Specifications
Haleon US Holdings LLC, operating from 184 Liberty Corner Rd, Warren, NJ 07059-6796, United States, is the entity responsible for this significant recall. While the specific manufacturing facility involved in the contamination event is not detailed in the public record, the responsibility for product quality ultimately lies with the recalling firm. The product at the center of this event is Robitussin Honey CF Max Nighttime Adult, a widely recognized over-the-counter (OTC) medication. Its active ingredients, Acetaminophen (650 mg) for pain relief and fever reduction, and Diphenhydramine HCl (25mg) for antihistamine and sedative effects, are common in nighttime cold and flu formulations. The recall was initiated on December 26, 2023, with the FDA classifying it on February 7, 2024. For procurement teams, understanding the exact product specifications, including active ingredients and dosage, is crucial for identifying potential substitute products or alternative suppliers. This event underscores the necessity of stringent quality agreements with contract manufacturers and internal production sites, even for non-sterile liquid pharmaceuticals. Regulatory affairs heads should review their quality management systems, particularly environmental monitoring and microbial control strategies, to ensure compliance and prevent similar incidents. Business development executives should assess the competitive landscape for OTC cough and cold remedies, as consumer trust in the Robitussin brand may be temporarily impacted, creating opportunities for competitors with robust quality records.
Supply Chain Exposure: Nationwide Impact of a Class I Contamination Event
The nationwide distribution pattern of the recalled 21,900 bottles of Robitussin Honey CF Max Nighttime Adult means that the supply chain impact is broad and immediate across the United States. The Class I classification elevates the urgency of this event, as it implies a high probability of serious health risks, including potential death, from consuming the contaminated product. This necessitates rapid identification, isolation, and removal of affected stock from pharmacies, retailers, and consumer homes. The affected lots, T08740 and T08742, were produced with an expiration date extending to June 30, 2026, indicating a potential long shelf-life for the contaminated product if not promptly recalled. For supply chain VPs, this incident highlights vulnerabilities in end-to-end product traceability and recall execution capabilities. The ability to quickly identify where affected products were shipped and to facilitate their return is paramount. Procurement directors must assess their inventory of similar OTC products and, if necessary, activate contingency plans to secure alternative sources to prevent stockouts. Regulatory affairs heads should prepare for increased scrutiny from the FDA regarding their firm's recall effectiveness and the thoroughness of their root cause analysis. Business development executives should monitor public perception and competitor responses, as a swift and transparent recall process can mitigate long-term brand damage, while any perceived missteps could erode market share.
Mitigating Risk: Strategic Sourcing for Critical OTC Formulations
The ChemLifeIntel Knowledge Graph does not currently identify specific alternative suppliers for Robitussin Honey CF Max Nighttime Adult or its active ingredients (Acetaminophen and Diphenhydramine HCl) from Haleon US Holdings LLC. In the absence of direct alternatives, procurement teams must activate broader strategic sourcing initiatives. This involves a critical review of existing supplier diversification strategies for all key active pharmaceutical ingredients (APIs) and finished drug products, particularly those with high market demand like OTC cough and cold remedies. The qualification process for new suppliers for pharmaceutical products is rigorous, often requiring extensive audits, analytical testing, stability studies, and regulatory filings, which can span 12 to 24 months. For procurement directors, this event underscores the imperative of maintaining a robust pipeline of pre-qualified secondary and tertiary suppliers. Relying on a single source for critical formulations or APIs poses significant business continuity risks, as demonstrated by this Class I recall. Supply chain VPs should invest in advanced supply chain mapping technologies to identify potential single points of failure and develop proactive mitigation strategies. Regulatory affairs heads must be prepared to manage the regulatory complexities associated with changing suppliers, including filing variations and ensuring new sources meet all cGMP requirements. Business development executives should consider partnerships or licensing agreements to broaden product portfolios and reduce reliance on specific formulations or manufacturers that may face quality challenges.
Regulatory Compliance and Risk Profile: Implications of a Class I Recall
While the ChemLifeIntel Knowledge Graph does not contain specific prior regulatory actions such as Warning Letters or 483s directly linked to Haleon US Holdings LLC, a Class I recall is a severe regulatory event that significantly impacts a company's compliance profile. This classification by the FDA indicates a fundamental breakdown in quality control systems that allowed microbial contamination in a non-sterile product, posing a direct and serious threat to patient health. Such an event typically triggers intensive internal investigations into manufacturing processes, environmental controls, raw material quality, and finished product testing protocols. For regulatory affairs heads, this means an immediate and comprehensive review of their Quality Management System (QMS) is required. Demonstrating a thorough root cause analysis and implementing effective corrective and preventive actions (CAPAs) will be critical to satisfying FDA scrutiny. Failure to adequately address the underlying issues could lead to further regulatory actions, including potential future inspections or enforcement. Business development executives should be aware that a Class I recall can erode consumer trust and brand equity, potentially impacting market share and future product launches. Supply chain VPs must ensure that quality assurance is deeply embedded in every stage of the supply chain, from raw material sourcing to final product distribution, to prevent such high-severity events.
Remediation Timeline and Future Regulatory Oversight
The recall initiated by Haleon US Holdings LLC on December 26, 2023, remains in an 'Ongoing' status, indicating that the firm is actively engaged in the process of removing the contaminated Robitussin Honey CF Max Nighttime Adult from the market and addressing the underlying issues. The FDA's classification of this as a Class I recall on February 7, 2024, underscores the agency's serious concerns regarding the potential health risks. Haleon is now obligated to conduct a thorough investigation to identify the precise source and nature of the microbial contamination, implement robust corrective actions, and provide regular updates to the FDA on the progress and effectiveness of these measures. For regulatory affairs heads, this period demands meticulous documentation of all remediation efforts, including revised manufacturing protocols, enhanced quality control testing, and employee training. The FDA will closely monitor these actions, and a failure to demonstrate effective remediation could lead to further regulatory enforcement, such as an official Warning Letter or even an Import Alert if products were manufactured overseas. Procurement directors should monitor the resolution of this recall to gauge the long-term reliability of Haleon as a supplier for similar products. Supply chain VPs should leverage this incident as a critical learning opportunity, integrating lessons learned into their risk management frameworks to enhance resilience against future quality-related disruptions and ensure continuous supply chain integrity.